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Abstract
The effect of Bcl-2 on oncogenesis is complex and expression may either delay or accelerate oncogenesis. The pro-
oncogenic activity is attributed to its well characterized anti-apoptotic function while the anti-oncogenic function has been
attributed to its inhibition of cellular proliferation. Recent studies demonstrate that p27 may mediate the effects of Bcl-2 on
cellular proliferation. We hypothesized that p27 may suppress tumor formation by Bcl-2 family members. To test this
hypothesis, cell cycle inhibition and lymphoma development were examined in Lck-Bcl-2 and Lck-Bax38/1 transgenic mice
deficient in p27. Strikingly, p27 deficiency synergistically cooperates with Bcl-2 to increase T cell hyperplasia and
development of spontaneous T cell lymphomas. Within 1 year, .90% of these mice had developed thymic T cell
lymphomas. This high penetrance contrasts with a one year incidence of ,5% of thymic lymphoma in Lck-Bcl-2 or p27 2/2
mice alone. In contrast, p27 deficiency had no effect on tumor formation in Lck-Bax38/1 transgenic mice, another model of
T cell lymphoma. Histologically the lymphomas in p27 2/2 Lck-Bcl-2 mice are lymphoblastic and frequently involve
multiple organs suggesting an aggressive phenotype. Interestingly, in mature splenic T cells, Bcl-2 largely retains its anti-
proliferative function even in the absence of p27. T cells from p27 2/2 Lck-Bcl-2 mice show delayed kinetics of CDK2 Thr-
160 phosphorylation. This delay is associated with a delay in the up regulation of both Cyclin D2 and D3. These data
demonstrate a complex relationship between the Bcl-2 family, cellular proliferation, and oncogenesis and demonstrate that
p27 up-regulation is not singularly important in the proliferative delay observed in T cells expressing Bcl-2 family members.
Nonetheless, the results indicate that p27 is a critical tumor suppressor in the context of Bcl-2 expression.
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Introduction
The Bcl-2 oncogene was discovered at the t(14;18) translocation
breakpoint in human B cell follicular lymphomas [1–3]. Bcl-2 is a
member of a large family of proteins that are critical regulators of
cell death. This family is comprised of both anti-apoptotic (Bcl-2,
Bcl-XL) and pro-apoptotic members (Bax, Bak) [4,5]. Bcl-2
predominantly resides at the outer mitochondrial membrane and
is able to block a number of mitochondrial changes that occur with
apoptosis such as loss of mitochondrial membrane potential
(DYm), release of mitochondrial proteins such as cytochrome C
and Apoptosis-Inducing Factor (AIF), and opening of the
mitochondrial permeability transition pore (PTP) [5,6]. Bcl-2 also
functions by preventing the formation of a complex that involves
pro-apoptotic family members such as Bak and Bax [7]. Due to its
anti-apoptotic function, Bcl-2 is thought to enhance oncogenesis
by prolonging the survival of cells with pre-tumorigenic lesions and
therefore increase the likelihood of malignancy [8].
Paradoxically, Bcl-2 expression is not always correlated with
accelerated oncogenesis and a poor clinical outcome. In studies of
human colon cancer [9–13] and breast cancer [14] increased Bcl-2
expression correlated with prolonged survival. In mouse models of
cancer, Bcl-2 expression resulted in delayed tumor development in
c-myc driven hepatocellular carcinoma [15], dimethylbenz(a)an-
thracene induced mammary tumors [16], and UV or chemical
induced squamous cell carcinomas [17]. Moreover, we recently
demonstrated that Bcl-2 suppressed lymphoma formation and
chromosomal instability in transgenic mice expressing Bax
[18,19]. In many of these studies, the tumor-suppressive effect of
Bcl-2 correlated with decreased cellular proliferation.
A variety of studies have shown Bcl-2 has a significant anti-
proliferative effect on different cell types. In BAF3 cells following
IL-3 withdrawal, Bcl-2 expressing cells rapidly arrested in the G1
phase of the cell cycle and were refractory to re-stimulation when
IL-3 was added back [20]. Moreover, in both fibroblasts and IL-3
dependent cells arrested in G0, Bcl-2 expression increased the time
to reach S phase [21]. Bcl-2 was also shown to accelerate cell cycle
withdrawal into G0 [22]. Together, these findings demonstrate
that Bcl-2 regulates cellular proliferation by controlling the G0 to
G1 transition. Several studies on the effect of Bcl-2 on resting
lymphocytes are consistent with this interpretation. B-lymphocytes
isolated from Bcl-2 transgenic mice were resistant to activation and
proliferation in vitro [23–25]. Similarly, T cells isolated from Bcl-2
transgenic, wild-type, and deficient mice demonstrated an inverse
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more, in vivo, B-lymphocytes from Bcl-2 transgenic mice displayed
delayed activation following immunization [27].
An important point that remains controversial is whether the
same or distinct functions of Bcl-2 account for the anti-
proliferative and anti-apoptotic activities. In one study using cell
lines, a single point mutation at tyrosine 28 (to Ala, Ser, and Phe)
in the BH4 domain was able to ablate the anti-proliferative effect
without affecting the anti-apoptotic function of Bcl-2 [21]. In
contrast to this finding, other reports using this same mutation in
cell lines and in transgenic mice demonstrated a tight correlation
between the anti-apoptotic and anti-proliferative functions of Bcl-2
and demonstrated these two functions could not be separated
[28,29]. Alternatively, these reports suggest that cell cycle delay by
Bcl-2 depends on the prolonged in vivo survival of these cells which
results in reduced cell size and delayed cellular proliferation [29].
In multiple reports, molecular analysis of Bcl-2-mediated
inhibition of cell cycle has consistently shown that p27 protein
levels are elevated in cells expressing Bcl-2 [28–30]. P27 is a Cyclin
Dependent Kinase Inhibitor (CKI) and a member of the Cip/Kip
family [31]. In particular, p27 has been suggested to act by
inhibiting the activation of CDK2, a critical G1 kinase [31]. While
the mechanism by which Bcl-2 elevates p27 levels is unknown, one
study reported that Bcl-2 was unable to inhibit cellular
proliferation in p27 deficient cells [30]. These studies prompted
us to examine the role of p27 in both cell cycle control and
malignant transformation in mice over-expressing Bcl-2.
Here we report a striking synergistic cooperation between p27
deficiency and Bcl-2 in thymic lymphoma development. Despite
this synergy, Bcl-2 largely retains its anti-proliferative function in
p27 2/2 deficient splenic T cells from mice prior to lymphoma
development. These findings demonstrate a complex relationship
between p27 and Bcl-2 with regards to cellular proliferation, and
oncogenesis. The data show that up-regulation of p27 is not
singularly important in the proliferative delay observed in T cells
expressing Bcl-2. However, p27 functions as a critical tumor
suppressor in the context of enforced Bcl-2 expression in
thymocytes.
Results
T cell hyperplasia in p27 2/2 Lck-Bcl-2 mice
To examine whether p27 functions as a critical suppressor of
cell proliferation, lymphoid hyperplasia, and oncogenesis down-
stream of Bcl-2, p27 deficient mice were crossed to mice over-
expressing Bcl-2 in T cells (Lck-Bcl-2) [32]. Lymphoid hyperplasia
was assessed by determining the number of T cells (CD3 +) and B
cells (B220 +) present in the spleen [33]. As expected from previous
studies, both Lck-Bcl-2 and p27 2/2 mice had modestly enlarged
spleens and increased splenic T cells. However, the combination of
Lck-Bcl-2 and p27 2/2 deficiency proved synergistic as the
spleens were markedly enlarged (Figure 1A) and the number of
splenic T cells dramatically increased (Figure 1B). As expected,
Bcl-2 markedly prolonged in vitro T cell survival while p27
expression had no effect on survival with or without Lck-Bcl-2
(Figure 1C). Staining of splenic B and T cells demonstrates no
change in the percentage of T cells in p27 2/2 mice versus the
p27 +/2 control. In contrast, Bcl-2 expression markedly increased
the percentage of T cells with p27 2/2 mice showing an even
higher percentage than the p27 +/2 mice (Figure 2A). Previous
results had demonstrated that Bcl-2 decreases T cell size [26]
which was correlated with inhibition of cell cycle [29]. We
therefore examined whether the reduction in splenic T cell size as
measured by forward scatter was dependent upon p27. Bcl-2
Figure 1. Lymphoid hyperplasia in p27 2/2 Lck-Bcl-2 mice.
Spleens were dissected and T cells isolated from p27 2/2 Lck-Bcl-2
transgenic mice and analyzed for viability and total splenic T cells as
described in the Materials and Methods. Control groups included p27
2/2, p27 +/2, and p27 +/2 Lck-Bcl-2 mice. A) Representative images
of spleens from mice of the indicated genotypes. B) Total splenic T cells
were determined by staining with an anti-CD3 antibody as described in
the Materials and Methods. The Mean6SD of at least three mice is
shown for the genotypes indicated. * P value ,0.01 compared to all
three other groups. C) Purified T cells from mice of the indicated
genotypes were prepared and cultured as described in the Materials
and Methods. Viability was determined over time by using the Guava
Flow cytometer and Viacount reagent. The mean6SD for duplicate
samples are shown.
doi:10.1371/journal.pone.0001911.g001
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strains (Figure 2B).
Developmental regulation of thymocyte proliferation in
p27 2/2 mice
The large increase in splenic T cells prompted us to examine
thymocyte cellularity and proliferation. While we found large
variations in thymic cellularity even within the same genotype, on
average Bcl-2 expression reduced thymocyte cell number in
p27 +/2 mice while cell number was increased by Bcl-2 in
p27 2/2 mice (Figure 3A). We next examined the effect of p27
deficiency on the percentage of proliferating thymocytes (%S/G2/
M). For this data, we found an age dependent effect of Bcl-2 on
cell proliferation. In 4–6 week old mice, while Bcl-2 decreased the
percentage of cycling cells in both p27 +/2 and p27 2/2 mice,
the p27 2/2 cohort had significantly higher percentage of cycling
cells compared to the p27 +/2 group (Figure 3B). However, in 7–
12 week old mice, Bcl-2 inhibited thymocyte cell proliferation to
the same extent in either p27 +/2 or p27 2/2 mice (Figure 3C).
Figure 2. Splenic T cell hyperplasia and T cell size in p27 2/2
Lck-Bcl-2 mice. A) Total splenic cells from mice of the indicated
genotypes were isolated and stained with anti-B220-PE and anti-CD3-
FITC antibodies as described in the Materials and Methods. The
percentage of CD3-positive cells and the total number of splenic T cells
(total # of splenic cells X %CD3) is shown. The data are representative
of at least three mice from each genotype. B) The Mean Forward Scatter
of CD3 positive splenic T cells was determined by staining with an anti-
CD3 antibody as described in the Materials and Methods. The
Mean6SD of at least 5 mice is shown for the genotypes indicated.
*P ,0.01 versus both the p27 +/2 and p27 2/2 mice using the
unpaired Students T test. The p27 +/2 Lck-Bcl-2 mice were not
significantly different than the P27 2/2 Lck-Bcl-2 mice (P=0.89).
doi:10.1371/journal.pone.0001911.g002
Figure 3. Thymocyte cellularity and cell cycle in p27 2/2 Lck-
Bcl-2 mice. A) Total thymocyte cellularity from mice of the indicated
genotypes (Mean +/2 SEM) between 4 and 12 weeks of age is shown.
B) DNA content analysis was performed on freshly isolated thymocytes
on mice of the indicated genotypes between 4 and 6 weeks of age. The
mean and SD of at least 3 mice per group is shown. * P,0.01 versus the
control p27 +/2, p27+/2 Lck-Bcl-2 and p27 2/2mice using the
unpaired Students T test. C) DNA content analysis was performed on
freshly isolated thymocytes on mice of the indicated genotypes
between 7 and 12 weeks of age. The mean and SD of at least 3 mice
per group is shown. # P,0.01 versus both the p27 +/2 and p27 2/2
mice using the unpaired Students T test. The p27 +/2 Lck-Bcl-2 mice
were not significantly different than the P27 2/2 Lck-Bcl-2 mice in this
age group (P=0.94).
doi:10.1371/journal.pone.0001911.g003
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P27 has been proposed to be a critical mediator of the anti-
proliferative function of Bcl-2 [29,30]. To examine if p27 is
required for delayed proliferation in Lck-Bcl-2 transgenic mice,
purified splenic T cells from Lck-Bcl-2 p272/2 and control mice
were activated with immobilized anti-CD3 antibody. A time
course analysis demonstrated that Bcl-2 significantly delayed entry
into the cell cycle (%S/G2/M). Surprisingly, the cell cycle delay
by Bcl-2 was nearly equivalent in either p27 2/2 or p27 +/2
mice (Figure 4A). Examination of cell cycle by propidium iodide
(PI) staining in multiple independent experiments showed that the
percentage of cells that had entered the cell cycle was markedly
reduced by Bcl-2 even in p27 2/2 cells. This was true at either 24
or 40–42 hours (Figure 4B). When proliferation was measured by
3H-thymidine uptake, Bcl-2 effectively inhibited proliferation in
p27 +/2 and p27 2/2 cells (Figure 4C).
Delayed CDK2 phosphorylation in Bcl-2 T cells is
independent of p27
Previous results suggested that Bcl-2 delayed cell cycle correlates
with delayed CDK2 activation [34]. This delay has been
attributed at least in part to the elevation of p27 in cells expressing
Bcl-2. We therefore examined the effect of Bcl-2 on Thr-160
phosphorylation of CDK2 in cells deficient in p27. Phosphoryla-
tion at this site has been tightly correlated with activity and is
associated with a conformational change in the protein that can be
detected by SDS-PAGE [35]. As expected Bcl-2 significantly
delayed Thr-160 phosphorylation in p27 sufficient cells after CD3
activation. Surprisingly, a similar inhibition of CDK2 phosphor-
ylation is detected even in p27 2/2 T cells (Figure 5). For both
p27 +/2 and p27 2/2 cells, Thr-160 phosphorylation is largely
normalized 42 h after CD3 activation showing the delay is
transient. These results demonstrate that the delay in CDK2
phosphorylation by Bcl-2 is independent of p27 in this model.
Cyclin D2 and D3 expression is decreased in Lck-Bcl-2
transgenic mice
The progression from G0 to G1 requires the activation of D
cyclins prior to the phosphorylation/activation of CDK2. Since the
delay in CDK2 phosphorylation was independent of p27, the levels
of D type cyclins in Lck-Bcl-2 transgenic mice prior to and after
activation with CD3 were determined. Interestingly, there was no
change in cyclin D1 levels in T cells following anti-CD3 activation
(Figure6). However, both CyclinD2 and D3are markedlyincreased
29hafter activation with anti-CD3 inthe control cells notexpressing
Bcl-2. In contrast, T cells expressing Bcl-2 did not show an increase
in cyclin D2 and D3 29 h after activation. This was true for both p27
+/2 and p27 2/2 Bcl-2 expressing cells.
Bcl-2 and p27 deficiency cooperate in lymphoma
formation
Since previous studies implicated p27 in cell cycle regulation by
Bcl-2 [30] and our preliminary studies demonstrate dramatic
Figure 4. Bcl-2 retains anti-proliferative activity in p27 2/2 mice.
SplenicTcellswereisolated,purified,andactivatedwithimmobilizedanti-
CD3 antibody as described in the Materials and Methods. A) At the time
pointsindicated,TcellswereharvestedandanalyzedforcellcycleusingPI
staining. The %S/G2/M at each time point is shown. This experiment is
representative of at least three independent experiments. B) Shown is the
%S/G2/M (mean6SD) cell cycle analysis at 24 and 40–42 hours following
activation from multiple independent experiments from mice of the
indicated genotypes. The differences between the Lck-Bcl-2 samples (p27
+/2 vs p27 2/2) were not significant (NS). * P,0.01 versus the control
p27 +/2 and p27 2/2 mice using the unpaired Students T test. C)
Proliferation of T cells of the indicated genotypes was determined by
3H-thymidine uptake. Values represent Mean6SD of quintuplet samples.
All three groups are significantly different from one another witha P value
of ,0.01 using the Students T test.
doi:10.1371/journal.pone.0001911.g004
Figure 5. Bcl-2 inhibition of Cdk2 phosphorylation is indepen-
dent of p27. T cells from mice of the indicated genotypes were purified
and activated with immobilized anti-CD3 antibody prior to harvesting for
immunoblot analysis at the time indicated. Immunoblots for total Cdk2,
Phospho Thr-160, and Actin as a loading control are shown.
doi:10.1371/journal.pone.0001911.g005
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young p27 2/2 Lck-Bcl-2 mice, lymphoma formation was
examined in these animals. Previous studies found that lymphoma
formation is observed in Lck-Bcl-2 transgenic mice but significant
penetrance is not observed until after 1 year of age [36]. Similarly,
lymphoma formation is infrequent in p27 2/2 mice in the first year
of life [37]. In this study, p27 2/2 Lck-Bcl-2 and control groups
were monitored weekly for evidence of tumors. P27 2/2 Lck-Bcl-2
mice were highly susceptible to thymic lymphomas with complete
penetrance by 60 weeks of age. Consistent with previous reports,
lymphomas were infrequently detected in p27 +/2,p 2 72/2,o r
Lck-Bcl-2 transgenic mice during this time period (Figure 7).
P27 2/2 Lck-Bcl-2 thymic lymphomas are lymphoblastic
and involve multiple organs
Necropsies of the p27 2/2 Lck-Bcl-2 animals generally showed
a massively enlarged thoracic tumor that in all cases appeared to
arise within the thymus. Most animals were sacrificed due to
respiratory compromise/labored breathing from the tumor.
Histological examination of H&E stained tumors showed the
tumor contained lymphoblastic cells (Figure 8). Histological
examination of the tumors demonstrated locally invasive tumors
that frequently involved the kidneys and liver (Figure 8).
Immunohistochemical staining showed the tumor cells were
Thy1 positive and retained expression of human Bcl-2 (Figure 8).
These results confirm that the thoracic tumors are aggressive T
cell thymic lymphomas.
P27 deficiency fails to promote lymphoma development
in Lck-Bax38/1mice
In contrast to Bcl-2, Bax has been shown to have pro-apoptotic
function. Despite this pro-apoptotic activity, expression of Bax in
thymocytes accelerates T cell lymphoma development [18,38].
Given the cooperation between p27 deficiency and Bcl-2, the
effect of p27 deficiency on lymphoma formation in Lck-Bax38/1
transgenic mice was determined. In young mice, increased Bax
expression results in dramatic thymic lymphopenia concordant
Figure 7. Bcl-2 synergizes with p27 deficiency to rapidly
promote lymphoma formation. Mice of the indicated genotype
were followed for thymic tumor free survival as described in the
Materials and Methods. Kaplan-Meier lymphoma free survival analysis of
mice of the indicated genotypes is shown. Lymphoma formation in p27
2/2 Lck-Bcl-2 mice was significantly (P,0.01) accelerated compared to
all three of the control groups (p27 +/2, p27 2/2, and p27 +/2 Lck-
Bcl-2). The other three groups were not significantly different from one
another with regards to survival due to thymic tumors. As previously
reported, a subset of p27 2/2 mice did succumb to pituitary adenomas
but these animals had no evidence of thymic lymphomas and were
censored from this analysis of lymphoma formation (data not shown).
doi:10.1371/journal.pone.0001911.g007
Figure 8. Tumors from p27 2/2 Lck-Bcl-2 mice are aggressive T
cell lymphoblastic lymphomas. Histological analysis of the thoracic
tumors from the p27 2/2 Lck-Bcl-2 mice is shown as indicated. H&E
staining shows a characteristic lymphoblastic lymphoma (Top left) that
were frequently locally invasive (Heart) and involved distant organs
such as the kidney and liver. Immunohistochemistry staining of the liver
confirms the tumors are of T cell origin (Thy1 positive) and retain
expression of human BCL-2.
doi:10.1371/journal.pone.0001911.g008
Figure 6. Bcl-2 delays the upregulation of Cyclins D2 and D3
independent of p27. T cells from mice of the indicated genotypes
were purified and activated with immobilized anti-CD3 antibody prior
to harvesting for immunoblot analysis at the time indicated.
Immunoblots for total Cyclin D1, Cyclin D2, Cyclin D3, and Actin as a
loading control are shown.
doi:10.1371/journal.pone.0001911.g006
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2/2 mice. This was true for both control and Lck-Bax38/1
transgenic mice (Figure 9A). However, in contrast to Lck-Bcl-2
mice, p27 deficiency had no affect on the development of
lymphoma formation in Lck-Bax38/1 transgenic mice (Figure 9B).
Discussion
Numerous studies in both humans and mice have shown
paradoxical effects of Bcl-2 on tumor formation. Several studies
have attributed these paradoxical effects to the anti-proliferative
activity of Bcl-2. Bcl-2 mediated inhibition of proliferation has
been tightly correlated with the anti-apoptotic function of Bcl-2
and to increased levels of p27 [28–30]. In fact, in one model Bcl-2
expression was unable to inhibit T cell proliferation in p27
deficient cells [30]. These studies prompted us to determine if p27
is an important tumor suppressor downstream of Bcl-2. In this
study, we hypothesized that p27 deficiency would cooperate with
Bcl-2 in tumor formation. Consistent with this hypothesis,
lymphoma formation was dramatically accelerated by combining
the loss of p27 with the expression of Bcl-2.
CKI’s inhibitors include both the Cip/Kip [39] and INK4 [40]
families. For the INK family, p16 has been clearly shown to be a
tumor suppressor [40,41]. For the members of the Cip/Kip
family, their roles as bonafide tumor suppressors are not as well
established. P21 was one of the first known targets of p53 and as
such was proposed to act as a tumor suppressor. Surprisingly, p21
deficient mice failed to develop tumors at a significant rate [42,43].
Similarly, p27 deficient mice demonstrate multiple defects in
growth control but are not particularly prone to tumor formation
[37,44]. Though some of the mice develop pituitary adenomas,
spontaneous aggressive malignancies are rare. However, p27
deficient mice are prone to develop aggressive malignancies when
combined with a deletion in tumor suppressor genes such as p53
or INK4a/ARF, or when challenged with mutagens such as X-
irradiation or N-ethyl-N-nitrosourea (ENU) [45–47]. Moreover,
lymphoma formation was rapidly accelerated in p27 deficient mice
expressing the dominant oncogenes myc (Em-myc mice) or cyclin E
[48,49]. Together, these findings demonstrate that the absence of
p27 by itself is not predominantly oncogenic; however, p27
deficiency can sensitize mice to other oncogenic insults. The study
described here extends these studies and demonstrates that p27 is
an important tumor suppressor in the context of Bcl-2 expression.
In contrast to the result with Bcl-2, the absence of p27 had no
impact on lymphoma formation in mice expressing pro-apoptotic
Bax. The data clearly show that complete elimination of p27 had no
additive effect on tumor formation and only a modest increase in
thymiccellularityinyoung Lck-Bax38/1 mice. These results support
the idea that Bax and Bcl-2 mediate tumor formation by distinct
pathways, consistent with their opposing function in regulating cell
death. Previous studies have shown that Bcl-2 expression maintains
genomestabilitybyabrogatingtheselectivepressure(s)neededtolose
p53 in experimental tumor models [50,51]. However, the Bcl-2
family has paradoxical effects on lymphoma formation and
chromosomal instability even in p53 2/2 mice [18,19]. These
data demonstrate the paradoxical effects of the Bcl-2 family are in
some cases independent of p53 and suggest that the effects of Bcl-2
on tumor formation are not singularly dependent on whether the
tumors retain or lose p53. These studies in mice are consistent with a
recent study of human breast cancer that showed Bcl-2 expression
provides a favorable prognosis independent of several risk factors
including the Nottingham Prognostic Index and was a more
important prognostic factor than p53 status [52].
The ability of Bcl-2 to retain its cell cycle inhibitory affect on
splenicTcellsintheabsenceofp27wassurprising.Apreviousreport
had found that Bcl-2 expression in T cells was unable to inhibit
3H-thymidine uptake in p27 deficient cells [30]. This is in contrast to
our findings that Bcl-2 effectively inhibits splenic T cell proliferation
as measured by cell cycle analysis of PI stained nuclei or
3H-thymidine uptake in p27 deficient cells. While the explanation
for this discrepancy is not clear, one possibility may be that the
studies employed different transgenic mouse models. Our study
utilized the Lck promoter and the study by Vairo et. al. used a Em-
promoter. It is possible that Bcl-2 expression is higher in the Lck
model and the singularly important role of p27 is apparent at lower
levels of Bcl-2 expression. In any case, we did find a role for p27 in a
developmentally dependent manner. We demonstrated that Bcl-2
more effectively inhibited thymocyte proliferation in p27 +/2 mice
Figure 9. p27 deficiency does not accelerate lymphoma
formation in Lck-Bax38/1 mice. A) Thymic cellularity from young
mice of the indicated genotypes is shown. Data represent the
Mean6SD of at least four animals from each group. In all cases, Lck-
Bax38/1 mice had significantly reduced cellularity compared to the
three transgene negative control groups shown on the left. *P,0.05 vs
the respective p27 +/+ and p27 +/2 controls. B) Kaplan-Meier analysis
for lymphoma free survival comparing p27 2/2 Lck-Bax38/1 (¤) and
p27 +/2 Lck-Bax38/1 (D) mice is shown.
doi:10.1371/journal.pone.0001911.g009
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These differences between mice with and without p27 were not
observed in older mice between 7 and 12 weeks of age. These results
suggest that the effects of p27 inthis model are age dependent and as
the animal ages, the extent of T cell hyperplasia becomes more
pronounced. The cells are then reduced insizeand p27 independent
pathways are able to inhibit T cell proliferation. Our studies suggest
that delayed up regulation of CyclinD2 and Cyclin D3 may mediate
the p27 independent cell cycle inhibition by Bcl-2.
The results described confirm and extend our previous report in
which inhibition of T cell proliferation by Bcl-2 was dependent upon
the age of the mouse, the extent of T cell hyperplasia and the
reduction in T cell size [29]. In our working model, we propose that
a decreaseinasurvival/proliferativesignalresultsinareductioninT
cell size and a delay in cell proliferation. For T cells, the in vivo
survival/proliferative signal may involve interactions between the T
Cell Receptor (TCR) on the T cells with the Major Histocompat-
ibility Complex (MHC) on antigen presenting cells (APCs) [53].
When Bcl-2 is expressed, the selective reduction of T cell death leads
to an increase in the ratio of T Cells to APC’s in an age dependent
manner. This altered ratio decreases the TCR/MHC interactions,
results in the reduction in T cell size and delayed proliferation. Our
studiesshowtheprimaryfunctionofp27istoregulatetheextentofT
cell hyperplasia while inhibition of T cell size and cell cycle remains
intact even in p27 deficient mice.
The studies here demonstrate that Bcl-2 significantly delays the
increase in expression of both Cyclin D2 and Cyclin D3 in a manner
that is independent of p27. This delay correlates with a delay in
Cdk2phosphorylation whichhasbeentightly linked to exit from G1.
This data provide yet another mechanism by which Bcl-2 may
inhibit cell cycle inaddition to the p27 and p130 pathways [30]. The
studies here have not addressed the mechanism by which Bcl-2
delays the up-regulation of Cyclin D2 and D3. However, other
studiesshow the levelsof the CyclinD family arecontrolled byeither
protein stability [54] or mRNA levels [55]. In summary, these data
demonstrate a complex relationship between the Bcl-2 family,
cellular proliferation, and oncogenesis and demonstrate that p27 up-
regulation is not singularly important in the Bcl-2 mediated
proliferative delay observed in T cells. Nonetheless, the results
indicate that p27 plays a critical role in tissue homeostasis and in
tumor development in the context of Bcl-2 expression.
Materials and Methods
Transgenic mice
Lck-Bcl-2 and Lck-Bax38/1 were previously described and
were genotyped by PCR [33,38]. Lck-Bax38/1 are mice that
harbor two independent transgenic Bax constructs as previously
described [18]. P27 deficient mice [45] were obtained from
Jackson Labs (Stock #003122) and were genotyped by PCR as
recommended by Jackson Labs.
Tumor development studies
All mice were maintained in the animal facility at the University of
Iowa under an approved protocol (ACURF #0310191). Mice of the
appropriate genotypes were mated to obtain animals for the tumor
development studies. Littermate controls or controls from the same
matingpairswere used forallthesestudies.Whenpossible,p272/2
mice were used for matings to provide the highest percentage of
transgene positive-p27 deficient mice. Therefore, p27 +/2 mice
wereused as controls. Upon entryinto the tumordevelopment study,
animals wereexamined weeklyforsigns of illnessormalignancy. Sick
animals were monitored more frequently and euthanized when
necessary to prevent unnecessary suffering. Control animals were
monitored for at least one year and then killed for necropsy. These
animals did not show any evidence of lymphoma and were all
censored from the analysis of tumor free survival. When possible,
necropsies were performed on dead animals to determine if the
animals had gross evidence of lymphoma. Tumors were then
confirmed by fixation with formalin and histological examination
afterH&E staining.Allmice weremaintained inthe animalfacilityat
the University of Iowa (Iowa City, IA). Statistical analysis was
performed with the StatView Program (SAS Institute Inc.) using
Kaplan-Meier cumulative survival and the Logrank (Mantel-Cox)
test to determine if differences in survival were significant between
each of the indicated groups.
Cell preparation, analysis and CD3 activation
Single cell suspensions from either the spleen or thymus were
prepared by dispersing the organ between two glass slides in PBS.
Red blood cells were removed by 5-minute incubation in hypotonic
lysis buffer (0.83% NH4Cl, 10 mM Tris/pH 7.2). The viable cell
counts for both the thymus and the spleen were determined using a
hemocytometerandtrypan blueexclusionorusingViacount reagent
with the Guava flow cytometer (Guava Technologies, Hayward,
California, USA) as previously described [56]. Splenic T cells were
quantified by staining the cells with anti-CD3 (eBioscience #16-
0031) and anti-B220 (eBioscience #12-0452) antibodies and
analyzed by flow cytometry as previously described [33]. For cell
size determination, the mean fluorescence intensity of the forward
scatter parameter (FSC) was determined for the CD3 positive cells.
At least 5 mice between 5 and 12 weeks of age was recorded for each
of the 4 groups. Differences between groups were determined by the
t-Test assuming unequal variance (within Microsoft excel). Total
splenic T cells were calculated by multiplying the %CD3-positive by
the total number of splenic cells.
Splenic T cells were purified using reagents and protocols from
Stem Cell Technologies (Product #13051) as previously described
[29,57]. Cell purity was generally greater than 95% based on CD3-
positive staining. Purified T cells (0.5 to 1.0 million cells/ml) were
seeded onto either 96 well plates (0.2 ml for cell cycle studies) or 6
well plates (5–6 ml for immunoblots) that were pre-coated with
saturating amounts of anti-CD3 antibody (145-2C11 eBioscience
#16-0031-85). Cells were cultured in RPMI-1640 supplemented
with 10% FBS, 0.1 mM 2-mercaptoethanol, 200 mM glutamine,
and penicillin/streptomycin. At various times following activation,
cells were harvested and prepared for analysis. Cell cycle PI staining
and
3H-thymidine analysis was performed as previously described
[29]. Cell viability was performed in duplicate using the Guava Flow
cytometer and the ViaCount reagent as previously described [56].
For immunoblot analysis, cells were harvested, lysates prepared, and
blots performed as previously described [29]. Antibodies used for
immunoblot analysis were purchased as follows: pCDK2-Thr-160
(Cell Signaling Technology #2561S); CDK2 (Santa Cruz #SC-
163); Actin (Sigma #A4700); Cyclin D1 (Sigma #C7464); Cyclin
D2 (Sigma #C7339); cyclin D3 (BD Pharminigen #610279).
Acknowledgments
Transgenic mice were generated and maintained at the University of Iowa
Transgenic Animal Facility that is supported in part by the Roy J. and
Lucille P. Carver College of Medicine. We acknowledge Sean Martin,
Matthew Kemp, Agniezka Wydra, and Peter Harris for expert technical
assistance and animal husbandry.
Author Contributions
Conceived and designed the experiments: CK NC Cv. Performed the
experiments: NC Cv. Analyzed the data: CK NC Cv. Wrote the paper:
CK Cv.
p27 Suppresses Bcl-2 Lymphoma
PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e1911References
1. Cleary ML, Sklar J (1985) Nucleotide sequence of a t(14:18) chromosomal
breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster
region near a transcriptionally active locus on chromosome 18. Proc Natl Acad
Sci U S A 82: 7439–7443.
2. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, et al. (1985) Cloning
the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH
on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899–906.
3. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM (1985) The t(14:18)
chromosome translocations involved in B-cell neoplasms result from mistakes in
VDJ joining. Science 229: 1390–1393.
4. Chao DT, Korsmeyer SJ (1998) BCL-2 Family -Regulators of Cell Death.
Annual Review of Immunology 16: 395–419.
5. Kuwana T, Newmeyer DD (2003) Bcl-2-family proteins and the role of
mitochondria in apoptosis. Current Opinion in Cell Biology 15: 691–699.
6. Breckenridge DG, Xue D (2004) Regulation of mitochondrial membrane
premeabilization by BCL-2 family proteins and caspases. Current Opinion in
Cell Biology 16: 647–652.
7. Harris MH, Thompson CB (2000) The role of the Bcl-2 family in the regulation
of outer mitochondrial membrane permeability. Cell Death & Differentiation 7:
1182–1191.
8. MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M, Packham G
(1999) Bcl-2-related proteins and cancer. Biochemical Society Transactions 27:
785–789.
9. Meterissian SH, Kontogiannea M, Al-Sowaidi M, Linjawi A, Halwani F, et al.
(2001) Bcl-2 is a useful prognostic marker in Dukes’ B colon cancer. Annals of
Surgical Oncology 8: 533–537.
10. Buglioni S, D’Agnano I, Cosimelli M, Vasselli S, D’Angelo C, et al. (1999)
Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas:
Independent prognostic role of p53 and Bcl-2. International Journal of Cancer
84: 545–552.
11. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, et al. (1997) Prognostic
significance of bcl-2 expression and p53 nuclear accumulation in colorectal
adenocarcinoma. International Journal of Cancer 74: 346–358.
12. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, et al. (1995)
Immunohistochemically detectable bcl-2 expression in colorectal carcinoma-
correlation with tumour stage and patient survival. British Journal of Cancer 72:
981–985.
13. Kaklamanis L, Savage A, Whitehouse R, Doussis-Anagnostopoulou I,
Biddolph S, et al. (1998) Bcl-2 protein expression: association with p53 and
prognosis in colorectal cancer. British Journal of Cancer 77: 1864–1869.
14. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, et al. (1994) The
bcl-2 protein-a prognostic indicator strongly related to p53 protein in lymph
node-negative breast cancer patients. Journal of the National Cancer Institute
86: 499–504.
15. de la Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, et al. (1999)
Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic
mice. Cancer Research 59: 5017–5022.
16. Murphy KL, Kittrell FS, Gay JP, Jager R, Medina D, et al. (1999) Bcl-2
expression delays mammary tumor development in dimethylbenz(a)anthracene-
treated transgenic mice. Oncogene 18: 6597–6604.
17. Rossiter H, Beissert S, Mayer C, Schon MP, Wienrich BG, et al. (2001)
Targeted expression of bcl-2 to murine basal epidermal keratinocytes results in
paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis.
Cancer Research 61: 3619–3626.
18. Luke JJ, Van de Wetering CI, Knudson CM (2003) Lymphoma development in
Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal
instability. Cell Death & Differentiation 10: 740–748.
19. van de Wetering CI, Knudson CM (2007) Chromosomal instability and
supernumerary centrosomes represent precursor defects in a mouse model of T-
cell lymphoma. Cancer Res 67: 8081–8088.
20. Marvel J, Perkins GR, Lopez Rivas A, Collins MK (1994) Growth factor
starvation of bcl-2 overexpressing murine bone marrow cells induced
refractoriness to IL-3 stimulation of proliferation. Oncogene 9: 1117–1122.
21. Huang DC, O’Reilly LA, Strasser A, Cory S (1997) The anti-apoptosis function
of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry.
EMBO Journal 16: 4628–4638.
22. Vairo G, Innes KM, Adams JM (1996) Bcl-2 has a cell cycle inhibitory function
separable from its enhancement of cell survival. Oncogene 13: 1511–1519.
23. O’Reilly LA, Huang DC, Strasser A (1996) The cell death inhibitor Bcl-2 and its
homologues influence control of cell cycle entry. EMBO Journal 15: 6979–6990.
24. O’Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A (1997)
Expression of a Bcl-2 transgene reduces proliferation and slows turnover of
developing B lymphocytes in vivo. Journal of Immunology 159: 2301–2311.
25. O’Reilly LA, Harris AW, Strasser A (1997) bcl-2 transgene expression promotes
survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors.
International Immunology 9: 1291–1301.
26. Linette GP, Li Y, Roth KA, Korsmeyer SJ (1996) Crosstalk between cell death
and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. Proc Natl
Acad Sci U S A 93: 9545–9552.
27. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, et al. (1991)
Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and
elicits autoimmune disease. Proc Natl Acad Sci U S A 88: 8661–8665.
28. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng NL, Soucie EL, et al.
(2003) Bcl-x(L)/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell
cycle entry. EMBO Journal 22: 5459–5470.
29. Cheng NL, Janumyan YM, Didion L, Van Hofwegen C, Yang E, et al. (2004)
Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival.
Oncogene 23: 3770–3780.
30. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, et al. (2000) Bcl-2 retards
cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F
regulation. Molecular & Cellular Biology 20: 4745–4753.
31. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of
G1-phase progression. Genes & Development 13: 1501–1512.
32. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ (1991)
Bcl-2 inhibits multiple forms of apoptosis but not negative selection in
thymocytes. Cell 67: 879–888.
33. Knudson CM, Korsmeyer SJ (1997) Bcl-2 and Bax function independently to
regulate cell death. Nature Genetics 16: 358–363.
34. Greider C, Chattopadhyay A, Parkhurst C, Yang E (2002) BCL-x(L) and BCL2
delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1
cyclin-dependent kinases. Oncogene 21: 7765–7775.
35. Holmes JK, Solomon MJ (2001) The role of Thr160 phosphorylation of Cdk2 in
substrate recognition. Eur J Biochem 268: 4647–4653.
36. Linette GP, Hess JL, Sentman CL, Korsmeyer SJ (1995) Peripheral T-cell
lymphoma in lckpr-bcl-2 transgenic mice. Blood 86: 1255–1260.
37. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, et al. (1996) Mice
lacking p27(kip1) display increased body size, multiple organ hyperplasia, retinal
dysplasia, and pituitary tumors. Cell 85: 707–720.
38. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ (2001) Bax accelerates
tumorigenesis in p53-deficient mice. Cancer Research 61: 659–665.
39. Nakayama K, Nakayama K (1998) Cip/Kip cyclin-dependent kinase inhibitors:
brakes of the cell cycle engine during development. Bioessays 20: 1020–1029.
40. Roussel MF (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene
18: 5311–5317.
41. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, et al. (2001)
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
Nature 413: 86–91.
42. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. (1995)
Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:
552-557: 592.
43. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P (1995) Mice lacking
p21(c/p1/waf1) undergo normal development, but are defective in g1
checkpoint control. Cell 82: 675–684: 698.
44. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES,
et al. (1996) Enhanced growth of mice lacking the cyclin-dependent kinase
inhibitor function of p27(Kip1). Cell 85: 721–732.
45. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene
p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177–180.
46. Martin-Caballero J, Flores JM, Garcia-Palencia P, Collado M, Serrano M (2004)
Different cooperating effect of p21 or p27 deficiency in combination with
INK4a/ARF deletion in mice. Oncogene 23: 8231–8237.
47. Philipp-Staheli J, Kim K-H, Liggitt D, Gurley KE, Longton G, et al. (2004)
Distinct roles for p53, p27
Kip1, and p21
Cip1 during tumor development.
Oncogene 23: 905–913.
48. Martins CP, Berns A (2002) Loss of p27
Kip1 but not p21
Cip1 decreases survival
and synergizes with MYC in murine lymphomagenesis. EMBO J 21:
3739–3748.
49. Geisen C, Karsunky H, Yucel R, Moroy T (2003) Loss of p27
Kip1 cooperates
with cyclin E in T-cell lymphomagenesis. Oncogene 22: 1724–1729.
50. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, et al. (2002)
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1: 289–298.
51. Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, et al. (2002)
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2
eliminates selective advantages for p53-deficient cells in the tumor. Cancer
Biology & Therapy 1: 39–44.
52. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, et al. (2006) Bcl-2
Is a Prognostic Marker in Breast Cancer Independently of the Nottingham
Prognostic Index. Clin Cancer Res 12: 2468–2475.
53. Rathmell JC, Vander Heiden MG, Harris MH, Frauwirth KA, Thompson CB
(2000) In the absence of extrinsic signals, nutrient utilization by lymphocytes is
insufficient to maintain either cell size or viability. Molecular Cell 6: 683–692.
54. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer
development and the potential for therapeutic invention. Mol Cancer 6: 24.
55. Engedal N, Gjevik T, Blomhoff R, Blomhoff HK (2006) All-trans Retinoic Acid
Stimulates IL-2-Mediated Proliferation of Human T Lymphocytes: Early
Induction of Cyclin D3. J Immunol 177: 2851–2861.
56. Emerson DK, McCormick ML, Schmidt JA, Knudson CM (2005) Taurine
monochloramine activates a cell death pathway involving Bax and caspase-9.
Journal of Biological Chemistry 280: 3233–3241.
57. Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, et al. (2005) The role of low
molecular weight thiols in T lymphocyte proliferation and IL-2 secretion.
J Immunol 175: 7965–7972.
p27 Suppresses Bcl-2 Lymphoma
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e1911